HRP20170638T1 - MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI - Google Patents

MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI Download PDF

Info

Publication number
HRP20170638T1
HRP20170638T1 HRP20170638TT HRP20170638T HRP20170638T1 HR P20170638 T1 HRP20170638 T1 HR P20170638T1 HR P20170638T T HRP20170638T T HR P20170638TT HR P20170638 T HRP20170638 T HR P20170638T HR P20170638 T1 HRP20170638 T1 HR P20170638T1
Authority
HR
Croatia
Prior art keywords
methyl
compound
substituted
phenyl
chloro
Prior art date
Application number
HRP20170638TT
Other languages
English (en)
Inventor
Fangbin HAN
Hui Lei
Xichen Lin
Qinghua Meng
Yonghui Wang
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49709687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170638(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20170638T1 publication Critical patent/HRP20170638T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Claims (21)

1. Spoj Formule I ili njegova farmaceutski prihvatljiva sol [image] naznačen time što: R1 je: – C1-C6 alkil; – metil, supstituiran s i) C3-C5 cikloalkilom; ii) fenoksi; ili iii) fenilom i drugim supstituentom, kojeg se bira iz skupine koju čine: metil, halogen i metoksi; – etil, supstituiran s i) fenilom, gdje navedeni fenil može biti supstituiran s halogenom ili metoksi, ili ii) heteroarilom; – benzil, gdje fenilna skupina u navedenom benzilu može biti supstituirana s halogenom, metoksi ili SO2CH2CH3; – C2 alkenil, koji može biti supstituiran s jednim F i jednim fenilom; – C3-C7 cikloalkil, gdje navedeni cikloalkil može biti supstituiran s jednim ili dva supstituenta, koje se bira iz skupine koju čine fenil, metil i F; ili navedeni cikloalkil može biti kondenziran s fenilnim prstenom; – heterocikloalkil, koji može biti supstituiran s jednim ili dva C1-C3 alkil; – heteroaril, koji može biti supstituiran s jednim do dva supstituenta, koje se bira iz skupine koju čine: C1-C3 alkil, C1-C3 alkoksi i CF3; i – fenil, supstituiran s jednim do tri supstituenta, koje se bira iz skupine koju čine: i) halogen; ii) CN; iii) C1-C3 alkil, koji može biti supstituiran s jednim do tri F; iv) C1-C3 alkoksi; v) (CH2)nNRaRb; vi) C(O)CH3; i vii) CH2OCH3; R2 je halogen ili C1-C3 alkil; R3 je halogen ili metil; R4 je H ili metil; R5 je C1-C3 alkil; R6 je C1-C3 alkil; R7 se bira iz skupine koju čine: – C1-C7 alkil, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine halogen, C3-C5 cikloalkil i CF3; – C3-C7 cikloalkil, koji može biti supstituiran s jednim ili dva supstituenta, koje se bira iz skupine koju čine F, CH2F, CHF2, metil i metoksi, svaki k je 0 ili 1; svaki p je 0 ili 1; svaki n je 0, 1 ili 2; svaki Ra je H ili C1-C3 alkil; svaki Rb je H ili C1-C3 alkil.
2. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je R1 heteroaril, supstituiran s C1-C3 alkilom.
3. Spoj ili sol u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je R1 piridinil, supstituiran s metilom.
4. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je R2 metil.
5. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je k 1, a R3 je Cl ili F.
6. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je R4 H.
7. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je R5 metil.
8. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je p 0.
9. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je R7 C3-C6 cikloalkil, koji može biti supstituiran s jednim ili dva F ili metil.
10. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je R7 ciklobutil, supstituiran s metil ili dva F.
11. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je R7 ciklopentil.
12. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira između: (S)-N-(3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-5-fluor-2-metilfenil)-2-metilpirimidin-5-karboksamida; (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamida; (S)-3-cijano-N-(3-((4-(3,3-difluorciklobutankarbonil)-3-metilpiperazin-1-il)metil)-5-fluor-2-metilfenil)benzamida; (S)-N-(5-klor-3-((4-(2-ciklopropilacetil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamida; N-(5-fluor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-fluor-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-klor-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-klor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida; N-(5-klor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-2-metilpirimidin-5-karboksamida; N-(5-klor-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-2-metilpirimidin-5-karboksamida; i (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-2-metilpirimidin-5-karboksamida.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (S)-3-cijano-N-(3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-5-fluor-2-metilfenil)benzamid; ili njegova farmaceutski prihvatljiva sol.
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid; ili njegova farmaceutski prihvatljiva sol.
15. Spoj naznačen time što je (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid, Formule: [image] .
16. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je N-(5-klor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamid; ili njegova farmaceutski prihvatljiva sol.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
19. (S)-N-(5-Klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
20. Farmaceutski pripravak, naznačen time što sadrži spoj Formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu ili pomoćnu tvar.
21. Farmaceutski pripravak, naznačen time što sadrži (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid, kao i farmaceutski prihvatljivu podlogu ili pomoćnu tvar.
HRP20170638TT 2012-12-06 2017-04-24 MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI HRP20170638T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2012001636 2012-12-06
CN2013000182 2013-02-25
CN2013000803 2013-07-01
EP13799318.4A EP2928885B1 (en) 2012-12-06 2013-12-05 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
PCT/EP2013/075594 WO2014086894A1 (en) 2012-12-06 2013-12-05 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
HRP20170638T1 true HRP20170638T1 (hr) 2017-06-30

Family

ID=49709687

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170638TT HRP20170638T1 (hr) 2012-12-06 2017-04-24 MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI

Country Status (33)

Country Link
US (1) US10005731B2 (hr)
EP (2) EP3219711A1 (hr)
JP (1) JP6279605B2 (hr)
KR (1) KR20150092244A (hr)
CN (1) CN105121430B (hr)
AR (1) AR093818A1 (hr)
AU (1) AU2013354109B2 (hr)
BR (1) BR112015013137B1 (hr)
CA (1) CA2894016C (hr)
CL (1) CL2015001557A1 (hr)
CR (1) CR20150302A (hr)
CY (1) CY1118932T1 (hr)
DK (1) DK2928885T3 (hr)
EA (1) EA026437B1 (hr)
ES (1) ES2626390T3 (hr)
HK (1) HK1214814A1 (hr)
HR (1) HRP20170638T1 (hr)
HU (1) HUE033212T2 (hr)
IL (1) IL239082A0 (hr)
LT (1) LT2928885T (hr)
ME (1) ME02696B (hr)
MX (1) MX2015007180A (hr)
PE (1) PE20151144A1 (hr)
PH (1) PH12015501244A1 (hr)
PL (1) PL2928885T3 (hr)
PT (1) PT2928885T (hr)
RS (1) RS55875B1 (hr)
SG (1) SG11201504200TA (hr)
SI (1) SI2928885T1 (hr)
TW (1) TW201427959A (hr)
UY (1) UY35174A (hr)
WO (1) WO2014086894A1 (hr)
ZA (1) ZA201503666B (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
CA2938311C (en) 2014-02-03 2023-03-07 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
JP6759110B2 (ja) * 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物
EP3148985A4 (en) 2014-05-28 2018-01-17 GlaxoSmithKline Intellectual Property Development Limited Novel compounds
SG11201609722UA (en) * 2014-05-28 2016-12-29 Glaxosmithkline Ip Dev Ltd Novel compounds
CN104292208A (zh) * 2014-09-09 2015-01-21 上海师范大学 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
EA031967B1 (ru) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TW201625588A (zh) * 2014-11-05 2016-07-16 第一三共股份有限公司 環狀胺衍生物
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3250570A1 (en) 2015-01-30 2017-12-06 Pfizer Inc Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN109476653B (zh) * 2016-07-13 2022-04-22 利奥制药有限公司 类视黄醇相关孤儿受体γ的杂芳族调节剂
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途
EP3619188B1 (en) 2017-07-18 2020-10-07 Lonza Ltd Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN108752185A (zh) * 2018-07-17 2018-11-06 成都道合尔医药技术有限公司 一种1-氟-环戊甲酸的合成方法
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
CN110862319A (zh) * 2019-12-04 2020-03-06 深圳振强生物技术有限公司 奥扎格雷杂质的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2511263A1 (en) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
AR086156A1 (es) 2011-04-28 2013-11-20 Japan Tobacco Inc Compuesto de amida y su uso medicinal
US9586928B2 (en) * 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
PE20142400A1 (es) 2012-04-27 2015-02-04 Glaxo Group Ltd Compuestos novedosos
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2015061515A1 (en) 2013-10-25 2015-04-30 Glaxosmithkline Llc Novel compounds
US10286000B2 (en) 2013-10-25 2019-05-14 St. Jude Children's Research Hospital, Inc. Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
SG11201609722UA (en) 2014-05-28 2016-12-29 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3148985A4 (en) 2014-05-28 2018-01-17 GlaxoSmithKline Intellectual Property Development Limited Novel compounds
JP6759110B2 (ja) 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な化合物

Also Published As

Publication number Publication date
SG11201504200TA (en) 2015-06-29
EP2928885B1 (en) 2017-03-22
ES2626390T3 (es) 2017-07-24
PT2928885T (pt) 2017-06-30
TW201427959A (zh) 2014-07-16
HK1214814A1 (zh) 2016-08-05
EP2928885A1 (en) 2015-10-14
CA2894016C (en) 2020-12-22
IL239082A0 (en) 2015-07-30
JP6279605B2 (ja) 2018-02-14
AU2013354109B2 (en) 2016-06-16
CN105121430B (zh) 2017-06-16
US10005731B2 (en) 2018-06-26
ME02696B (me) 2017-10-20
DK2928885T3 (en) 2017-05-15
LT2928885T (lt) 2017-05-25
ZA201503666B (en) 2016-02-24
WO2014086894A1 (en) 2014-06-12
US20150299121A1 (en) 2015-10-22
PE20151144A1 (es) 2015-08-02
EA026437B1 (ru) 2017-04-28
PH12015501244A1 (en) 2015-08-10
CR20150302A (es) 2015-08-10
MX2015007180A (es) 2015-10-14
BR112015013137B1 (pt) 2022-05-10
AU2013354109A1 (en) 2015-06-11
UY35174A (es) 2014-06-30
EA201591059A1 (ru) 2015-09-30
HUE033212T2 (hu) 2017-11-28
CN105121430A (zh) 2015-12-02
RS55875B1 (sr) 2017-08-31
BR112015013137A2 (pt) 2017-07-11
AR093818A1 (es) 2015-06-24
CA2894016A1 (en) 2014-06-12
CL2015001557A1 (es) 2015-10-02
CY1118932T1 (el) 2018-01-10
JP2016501250A (ja) 2016-01-18
PL2928885T3 (pl) 2017-09-29
EP3219711A1 (en) 2017-09-20
SI2928885T1 (sl) 2017-06-30
KR20150092244A (ko) 2015-08-12

Similar Documents

Publication Publication Date Title
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
HRP20200341T1 (hr) Bromodomenski (bet) inhibitori
JP2013510122A5 (hr)
HRP20171078T1 (hr) Derivati arilmetoksi izoindolina i pripravci koji ih sadrže, te postupci njihove uporabe
JP2016501250A5 (hr)
NZ603594A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
JP2014511892A5 (hr)
NZ627750A (en) Carbamate compounds and of making and using same
PE20110285A1 (es) Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
HRP20161103T1 (hr) Kemijski spojevi
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
PE20140836A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
JP2014511891A5 (hr)
EA201591675A1 (ru) Замещенные 7-азабициклы и их применение в качестве модуляторов рецепторов орексина
RU2015133450A (ru) Соединения имидазопиридина и их применение
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
RU2001125899A (ru) Фенильные и пиридинильные производные
JP2014507455A5 (hr)
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
JP2013509392A5 (hr)
AR049110A1 (es) Compuestos terapeuticos: piridina como andamiaje estructural
RU2014101464A (ru) Циклопропил-конденсированные-1,3-тиазепины в качестве ингибиторов васе 1 и(или) васе 2
RU2008129641A (ru) Ингибиторы ccr9 активности